<div class="namenda-article p3-2">
	<h2>NAMENDA&nbsp;XR<sup>&trade;</sup> Side Effects </h2>
	<p>The most common side effects associated with NAMENDA&nbsp;XR&trade; (memantine&nbsp;hydrochloride) treatment are headache, diarrhea, and dizziness. This is not a complete list of side effects.</p>
	<h3>Most Common Side Effects of NAMENDA&nbsp;XR</h3>
	<p>The most common side effects occurring in a clinical trial in at least 2% of patients treated with NAMENDA&nbsp;XR and at a greater rate than in patients given placebo (a sugar pill) are listed in the chart below. Headache, diarrhea, and dizziness occurred at a rate of at least 5% in NAMENDA&nbsp;XR-treated patients and at a greater rate than in the placebo group. </p>
	<table class="graph2" cellspacing="0" cellpadding="0">
		<thead>
			<tr>
				<th>Side Effect</th>
				<th><span class="nowrap">NAMENDA&nbsp;XR 28 mg+AChEI</span><br>
					(n=341)<br>
					%</th>
				<th><span class="nowrap">Placebo+AChEI</span><br>
					(n=335)<br>
					%</th>
			</tr>
		</thead>
		<tr class="subhead">
			<th>Gastrointestinal disorders</th>
			<th>&nbsp;</th>
			<th>&nbsp;</th>
		</tr>
		<tr>
			<th>Diarrhea</th>
			<td>5</td>
			<td>4</td>
		</tr>
		<tr>
			<th>Constipation</th>
			<td>3</td>
			<td>1</td>
		</tr>
		<tr>
			<th>Abdominal Pain</th>
			<td>2</td>
			<td>1</td>
		</tr>
		<tr>
			<th>Vomiting</th>
			<td>2</td>
			<td>1</td>
		</tr>
		<tr class="subhead">
			<th>Infections and infestations</th>
			<th>&nbsp;</th>
			<th>&nbsp;</th>
		</tr>
		<tr>
			<th>Influenza</th>
			<td>4</td>
			<td>3</td>
		</tr>
		<tr class="subhead">
			<th>Investigations</th>
			<th>&nbsp;</th>
			<th>&nbsp;</th>
		</tr>
		<tr>
			<th>Weight, increased</th>
			<td>3</td>
			<td>1</td>
		</tr>
		<tr class="subhead">
			<th>Musculoskeletal and connective tissue disorders</th>
			<th>&nbsp;</th>
			<th>&nbsp;</th>
		</tr>
		<tr>
			<th>Back pain</th>
			<td>3</td>
			<td>1</td>
		</tr>
		<tr class="subhead">
			<th>Nervous system disorders</th>
			<th>&nbsp;</th>
			<th>&nbsp;</th>
		</tr>
		<tr>
			<th>Headache</th>
			<td>6</td>
			<td>5</td>
		</tr>
		<tr>
			<th>Dizziness</th>
			<td>5</td>
			<td>1</td>
		</tr>
		<tr>
			<th>Somnolence*</th>
			<td>3</td>
			<td>1</td>
		</tr>
		<tr class="subhead">
			<th>Psychiatric disorders</th>
			<th>&nbsp;</th>
			<th>&nbsp;</th>
		</tr>
		<tr>
			<th>Anxiety</th>
			<td>4</td>
			<td>3</td>
		</tr>
		<tr>
			<th>Depression</th>
			<td>3</td>
			<td>1</td>
		</tr>
		<tr>
			<th>Aggression</th>
			<td>2</td>
			<td>1</td>
		</tr>
		<tr class="subhead">
			<th>Renal and urinary disorders</th>
			<th>&nbsp;</th>
			<th>&nbsp;</th>
		</tr>
		<tr>
			<th>Urinary incontinence</th>
			<td>2</td>
			<td>1</td>
		</tr>
		<tr class="subhead">
			<th>Vascular disorders</th>
			<th>&nbsp;</th>
			<th>&nbsp;</th>
		</tr>
		<tr>
			<th>Hypertension</th>
			<td>4</td>
			<td>2</td>
		</tr>
		<tr>
			<th>Hypotension</th>
			<td>2</td>
			<td>1</td>
		</tr>
	</table>
	<p class="ref">*Drowsiness</p>
	<p>Discontinuation due to side effects was 10% for the NAMENDA&nbsp;XR 28 mg+AChEI treatment group and 6.3% for the placebo+AChEI treatment group. The most common side effect that led to treatment discontinuation in this study was dizziness, at a rate of 1.5% in the NAMENDA&nbsp;XR-treated group. </p>

</div>